Revvity, Inc. (RVTY)

Revvity's stock price has experienced fluctuations over the past six months. The stock price decreased by 4.44% in the past month and 9.23% over the last 12 months. Specific events impacting the stock include the announcement of financial results for Q4 and the full year of 2025, which reported revenue ahead of expectations, a decline in shares after the announcement of new global tariffs, the unveiling of its Signals BioDesign offering, and the announcement of an upcoming earnings call. The company's stock has been trading above its 50-day and 200-day moving averages since March 2026, suggesting a potential bullish trend.

Revvity's products and services exhibit some demand seasonality, with the fourth quarter typically being the strongest margin period. Management anticipates seasonal strength to support results in the fourth quarter, driven by higher software revenues and modest improvement in instrument volumes. The company's overall guide for the year is typically back-half weighted. However, ongoing reimbursement-related pressure in China Diagnostics and a cautious demand environment are expected to persist.

Revvity, Inc. is a global life sciences and diagnostics company providing technology-enabled solutions. It operates in life sciences, offering reagents, instruments, and services for biopharma and academic research, and diagnostics, providing tools for immunodiagnostics, newborn and reproductive health, and infectious disease detection. The company emerged in 2023 following a strategic split and rebranding from PerkinElmer, Inc.

Revvity has a significant global presence with facilities across North America, Europe, Asia-Pacific, and Latin America. Its products are sold worldwide, with major markets in the U.S., Europe, and China. Key operational hubs are located in Waltham, Hopkinton, and San Diego in the U.S., and Cambridge, Codolet, and Turku in Europe. The company also has active recruitment and operational centers in Cracow, Shanghai, and Mumbai. Net sales are geographically distributed as follows: America (44%), Europe (28.9%), and Asia (27.1%).

Revvity's brand reputation appears positive, with a focus on sustainability and social governance. The company released its annual Impact Report, highlighting achievements in sustainability, social, and governance initiatives, including reductions in emissions and waste. Revvity also earned a AAA ESG rating from MSCI and was recognized as a Great Place to Work® in multiple countries.

Revvity's ownership is predominantly institutional, with institutional investors holding approximately 97.4% of the company's shares. Major institutional owners include T. Rowe Price Investment Management, Inc., Vanguard Group Inc, and BlackRock, Inc. Alexis P. Michas is the largest individual shareholder, with 0.60% ownership.